<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400335</url>
  </required_header>
  <id_info>
    <org_study_id>TDC106222</org_study_id>
    <nct_id>NCT00400335</nct_id>
  </id_info>
  <brief_title>Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride</brief_title>
  <official_title>An Open Label Study to Evaluate the Impact of Novel Fixed-dose Testosterone/Dutasteride Combinations on the Relative Bioavailability of the Individual Dutasteride and Testosterone Components</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of testosterone and dutasteride is intended for use in hypogonadal men. This&#xD;
      study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone&#xD;
      administered with and without dutasteride&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lab tests for relative bioavailability of testosterone and dutasteride,</measure>
    <time_frame>days 1, 2, 3, 19, 20, 21 &amp; 26-31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety lab tests of various testosterone/dutasteride formulations,</measure>
    <time_frame>days 1, 2, 3, 19, 20, 21 &amp; 26-31.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lab tests for additional pharmacokinetic parameters for testosterone &amp; dutasteride,</measure>
    <time_frame>days 1, 2, 3, 19, 20, 21 &amp; 26-31.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Hypogonadism, Male</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanomilled testosterone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>commercially available dutasteride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanomilled dutasteride</intervention_name>
    <other_name>commercially available dutasteride</other_name>
    <other_name>Nanomilled testosterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Are healthy.&#xD;
&#xD;
          -  Have a BMI within range of 19-32 kg/m2.&#xD;
&#xD;
          -  Have not taken dutasteride for one year, or finasteride for the past 3 months.&#xD;
&#xD;
          -  Have a screening PSA &lt; 2.0ng/mL.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Have had or have breast or prostate cancer, sleep apnea, psychiatric illness, or any&#xD;
             other clinically significant current condition.&#xD;
&#xD;
          -  Have a trigliceride level =500mg/dL.&#xD;
&#xD;
          -  Have abnormal thyroid or hormone levels.&#xD;
&#xD;
          -  Would donate more than 500 ML of blood over a 2 month period.&#xD;
&#xD;
          -  Physician does not think it is a good idea for you to participate in the trial.&#xD;
&#xD;
          -  Are unwilling to abstain from alcohol during the study.&#xD;
&#xD;
          -  Have a positive urine drug screen test.&#xD;
&#xD;
          -  Plan to change your smoking habits during the course of the trial.&#xD;
&#xD;
          -  Have Hepatitis C, Hepatitis B, or HIV.&#xD;
&#xD;
          -  Have a lab or ECG abnormality.&#xD;
&#xD;
          -  Have high or low blood pressure.&#xD;
&#xD;
          -  Have used of any investigational drug or device during the study or within 30 days&#xD;
             prior to 1st dosing of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>November 14, 2006</study_first_submitted>
  <study_first_submitted_qc>November 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Men</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Dutasteride</keyword>
  <keyword>DHT</keyword>
  <keyword>Androgen deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

